pISSN 1226-6329 / eISSN 2733-4600
대한노인정신의학회 (29권2호 84-88)
Case Report on Clinical Features Within Six Months of Lecanemab Use
Lecanemab 사용 6개월 이내 임상양상 증례보고
IL Han Choo, MD, PhD
Department of Neuropsychiatry, College of Medicine, Chosun University, Gwangju, Department of Psychiatry, Chosun University Hospital, Gwangju, Korea
Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was approved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.
Lecanemab; Clinical; Alzheimer’s disease; Dementia.
PDF